Interim Results for the six months to 30 June 2025

Summary by AI BETAClose X

Poolbeg Pharma PLC announced its unaudited interim results for the six months to 30 June 2025, highlighting a strong financial position with a cash balance of £10.0 million, which includes £4.865 million gross proceeds from an oversubscribed fundraise. This extends the cash runway into 2027, supporting key clinical milestones. The loss for the period amounted to £2.2 million, which comprised of R&D expenses of £0.5 million and administrative expenses of £2.0 million. The company's total equity stands at £11.932 million. Basic and diluted loss per share was (0.43)p. Intangible assets were valued at £1.662 million.

Disclaimer*

UK 100

Latest directors dealings